PD1 ANTIBODIES AND THEIR APPLICATION METHODS Russian patent published in 2021 - IPC A61K39/395 C07K16/28 C12N15/13 C12N15/63 A61P35/00 

FIELD: medicine.

SUBSTANCE: group of inventions relates to immunology and medicine, in particular to PD1 antibodies and to methods of their application. Proposed is an isolated antibody that specifically binds to human PD1 and contains HVR-H1 containing amino acid sequence SEQ ID NO: 71; HVR-H2, containing amino acid sequence SEQ ID NO: 72; HVR-H3, containing amino acid sequence SEQ ID NO: 73; HVR-L1, containing amino acid sequence SEQ ID NO: 74; HVR-L2, containing amino acid sequence SEQ ID NO: 75; HVR-L3, containing amino acid sequence SEQ ID NO: 76, and FR-H3, containing amino acid sequence SEQ ID NO: 77 (RDN) at Positions 71, 72 и 73 according to the Kabat numbering. The PD1 antibody competes for binding to PD-1 with a PD1 antibody containing VH with the SEQ ID NO: 7 sequence and VL with the SEQ ID NO: 8 sequence, and / or binds to the PD-1 of humans and Javanese macaques; and /or enhances IFN-gamma secretion and/or enhances TNF alpha secretion by allogeneic stimulated T cells by 85% or more at the antibody concentration of 10 µg/ml. The proposed antibody exhibits reduced binding to human PD1, which is not glycosylated on Asn58 compared to binding to human PD1, glycosylated on Asn58.

EFFECT: antibody can be used to treat cancer.

16 cl, 14 dwg, 13 tbl, 10 ex